1. Home
  2. AEC vs CING Comparison

AEC vs CING Comparison

Compare AEC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AEC

Anfield Energy Inc.

HOLD

Current Price

$2.38

Market Cap

82.0M

Sector

Real Estate

ML Signal

HOLD

CING

Cingulate Inc.

SELL

Current Price

$5.03

Market Cap

70.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AEC
CING
Founded
1989
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.0M
70.2M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
AEC
CING
Price
$2.38
$5.03
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $21.20
AVG Volume (30 Days)
40.6K
★ 252.6K
Earning Date
05-01-2015
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 56.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$48.15
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$3.16
52 Week High
$10.24
$11.89

Technical Indicators

Market Signals
Indicator
AEC
CING
Relative Strength Index (RSI) 24.12 N/A
Support Level N/A N/A
Resistance Level $3.18 N/A
Average True Range (ATR) 0.19 0.00
MACD -0.04 0.00
Stochastic Oscillator 7.91 0.00

Price Performance

Historical Comparison
AEC
CING

About AEC Anfield Energy Inc.

Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: